Citation

Elling R, Spehl MS, Wohlfarth A, Auwaerter V, Hermanns-Clausen M. Clin. Toxicol. (Phila) 2015; 54(2): 158-160.

Affiliation

a Poison Information Center VIZ-Freiburg, Center of Pediatrics and Adolescent Medicine , University Medical Center Freiburg , Freiburg im Breisgau , Germany ;

Copyright

(Copyright © 2015, Informa - Taylor and Francis Group)

DOI

10.3109/15563650.2015.1122793

PMID

26692235

Abstract

CONTEXT: Repaglinide is a short-acting insulin secretagogue with high interindividual variability in pharmacokinetics due to genetic polymorphisms. Little is known about repaglinide overdoses, both with respect to pharmacokinetics and appropriate management. Given its short serum half-life of less than 1 h, hypoglycemic effects of repaglinide are expected to cease within a few hours post-ingestion. CASE DETAILS: A 15-year-old girl ingested 10.5 mg of repaglinide in a suicide attempt. Few hours later, she developed a strong food craving, nausea, abdominal pain, and a headache. The lowest recorded serum glucose was 44 mg/dl (2.4 mmol/l) 14 h post-ingestion. Using liquid chromatography-mass spectrometry, we detected repaglinide serum levels of 5.3, 2.6, and 1.0 ng/ml at 14, 20, and 26 h post-ingestion, respectively.

DISCUSSION: This case illustrates that in the context of overdose, repaglinide can lead to prolonged hypoglycemia. We therefore recommend glucose monitoring and observation for 24 h in all patients who remain hypoglycemic or show symptoms of hypoglycemia for an unusually long period of time.

Language: en